PARP Inhibition | sciencenewsnet.in

Breaking News

American Association of Immunologists (AAI) Introduces New Brand Identity

Stony coral tissue loss disease is shifting the ecological balance of Caribbean reefs

Metastatic Prostate Cancer Research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition

May is Mental Health Awareness Month. Experts and Patients Available for Interviews on Trending Issues

ChatGPT can be helpful for Black women’s self-education about HIV, PrEP

Tip Sheet: Funding awarded to two ovarian cancer research projects, progress towards liquid biopsies for lung cancer — and cannabis and alcohol use in patients

A Revolution In Gene Therapy Is Unfolding, Bringing Hope for Vision Loss

Mexican researchers have found that people who avoid going to psychologists choose the most violent suicide methods

Genetics, not lack of oxygen, causes cerebral palsy in quarter of cases

Leveraging Holocaust History to Influence Modern Healthcare Practice, Ethics

04 May, 2024

AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects

April 8, 2024 sarah JonasResearch Results

The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.